Duration of Aripiprazole Treatment After Psychosis
Based on current treatment guidelines, patients should continue aripiprazole for more than 1 year after a first psychotic episode, and more than 5 years after multiple psychotic episodes. 1
Evidence-Based Duration Recommendations
The maintenance treatment duration is stratified by episode history:
- First psychotic episode: Continue treatment for >1 year 1
- Multiple psychotic episodes: Continue treatment for >5 years 1
These recommendations are supported by relapse data showing that approximately two-thirds of patients relapse within 1 year of discontinuation, and nearly 90% may experience recurrence within 2 years if treatment is stopped prematurely. 1
Rationale for Extended Maintenance Treatment
The extended duration recommendations reflect the high relapse risk in schizophrenia spectrum disorders. Aripiprazole demonstrates favorable characteristics for long-term maintenance therapy, including:
- Comparable efficacy to other antipsychotics with lower incidence of parkinsonian symptoms 1
- Lack of prolactin elevation and decreased metabolic side effects 1
- Less weight gain compared to many alternatives 1
Dosing Considerations During Maintenance
For optimal relapse prevention, aripiprazole demonstrates effectiveness at moderate doses (0.6-<1.4 defined daily doses per day), which balances efficacy against adverse effects. 2 This dose range appears to provide the best real-world effectiveness for preventing psychotic relapse.
Critical Caveats
Switching from strong dopamine antagonists to aripiprazole requires careful management. 3 Due to aripiprazole's partial dopamine agonist properties, abrupt switching from full dopamine antagonists (like risperidone or paliperidone) can precipitate psychotic decompensation, even severe episodes including suicidality. 3 Gradual cross-titration is essential when transitioning to aripiprazole. 4
Long-acting injectable formulations are available for patients requiring enhanced adherence support, with monthly (400 mg) and 2-month (960 mg) options now approved. 5